Advanced PET imaging in oncology: status and developments with current and future relevance to lung cancer care

Purpose of review This review highlights the status and developments of PET imaging in oncology, with particular emphasis on lung cancer. We discuss the significance of PET for diagnosis, staging, decision-making, monitoring of treatment response, and drug development. The PET key advantage, the noninvasive assessment of functional and molecular tumor characteristics including tumor heterogeneity, as well as PET trends relevant to cancer care are exemplified. Recent findings Advances of PET and radiotracer technology are encouraging for multiple fields of oncological research and clinical application, including in-depth assessment of PET images by texture analysis (radiomics). Whole body PET imaging and novel PET tracers allow assessing characteristics of most types of cancer. However, only few PET tracers in addition to 18F-fluorodeoxyglucose have sufficiently been validated, approved, and are reimbursed for a limited number of indications. Therefore, validation and standardization of PET parameters including tracer dosage, image acquisition, post processing, and reading are required to expand PET imaging as clinically applicable approach. Summary Considering the potential of PET imaging for precision medicine and drug development in lung and other types of cancer, increasing efforts are warranted to standardize PET technology and to provide evidence for PET imaging as a guiding biomarker in nearly all areas of cancer treatment.
Source: Current Opinion in Oncology - Category: Cancer & Oncology Tags: LUNG AND MEDIASTINUM: Edited by Robert Pirker Source Type: research

Related Links:

Publication date: Available online 20 August 2018Source: NeurocomputingAuthor(s): Junjie Zhang, Yong Xia, Haoyue Zeng, Yanning ZhangAbstractDetection of pulmonary nodules on chest CT is an essential step in the early diagnosis of lung cancer, which is critical for best patient care. In this paper, we propose an automated pulmonary nodule detection algorithm, denoted by NODULe, which jointly uses a conventional method for nodule detection and a deep learning model for genuine nodule identification. Specifically, we first use multi-scale Laplacian of Gaussian (LoG) filters and prior shape and size constraints to detect nodul...
Source: Neurocomputing - Category: Neuroscience Source Type: research
ConclusionLow PNI predicts poor survival in LC patients.
Source: Clinica Chimica Acta - Category: Laboratory Medicine Source Type: research
Conditions:   Brain Metastases;   Lung Cancer Metastatic;   Breast Cancer Metastatic Intervention:   Biological: DCVax-Direct Sponsors:   Northwest Biotherapeutics;   Mayo Clinic Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Anorexia;   Non-Small Cell Lung Carcinoma;   Stage III Lung Cancer AJCC v8;   Stage IIIA Lung Cancer AJCC v8;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB  Lung Cancer AJCC v8 Interventions:   Drug: Anamorelin Hydrochloride;   Other: Placebo Sponsors: &nbs...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
This study was performed in the ICUs of two centers between 1 January 2008 and 31 December 2015. Demographic data, cancer type, causes of respiratory failure, comorbidities, APACHE II scores, treatments, and mortality rates were recorded. Results: A total number of 583 cancer patients (477 males) were enrolled from the two centers. Of those, 472 patients had lung cancer (81%), while 111 had extrapulmonary malignancies (19%), having similar mortality rates. Causes of respiratory failure were mostly invasion of the cancer itself in 84% of cases and due to infection in 12%. ICU mortality rate was 53% and the 1-year mo...
Source: Turkish Journal of Medical Sciences - Category: General Medicine Tags: Turk J Med Sci Source Type: research
ConclusionBoth AAA and Acuros XB calculated dose accurately for the largest lung tumor. For the smallest and regressing tumors, Acuros XB more accurately modelled the dose distribution compared to AAA.
Source: Practical Radiation Oncology - Category: Cancer & Oncology Source Type: research
LUNG cancer symptoms usually begin to show as the condition progresses, with no indications in the early stages. But when they do become apparent the most common sign is a cough, particularly one that won ’t go away or gets worse. There are seven symptoms of the disease all together to look out for.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Roche today announced that the China National Drug Administration (CNDA) has granted marketing authorisation for Alecensa ® (alectinib) as a monotherapy treatment for patients with anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer (NSCLC).
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
Authors: Li X, Yuan N, Lin L, Yin L, Qu Y Abstract Non-small cell lung cancer (NSCLC) is the most frequent type of human lung cancer; lung cancer is responsible for the highest rates of cancer-associated mortality in the world. Cysteine-rich angiogenic inducer-61 (CYR-61) has been identified as a tumorigenesis-, development- and metastasis-related gene, and is reported to enhance proliferation, migration and invasion through hepatocyte growth factor (HGF)-induced scattering and the metastasis-inducing HGF/Met signaling pathway in tumor cells and xenograft models. CYR-61 is a protein that promotes human lung cancer ...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
Authors: Zou X, Huang W Abstract A steroidal saponin named pennogenin 3-O-α-L-rhamnopyranosyl-(1→2) [α-L-rhamnopyranosyl-(1→4)]-β-D-glucoyranoside(TTB2) has been successfully separated from the n-BuOH extracts of Trillium tschonoskii Maxim and is able to induce cytotoxicity to some types cancer cells. The present study aimed to investigate how this novel saponinin duces cytotoxicity in malignant sarcoma cells and to clarify its molecular mechanisms of action. It was determined this steroidal saponin induced the apoptosis in Rh1 cells and activated caspase-3 and caspase-9. Additionally, it...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
More News: Cancer | Cancer & Oncology | Lung Cancer | Mergers and Aquisitions